126 related articles for article (PubMed ID: 37856198)
1. Validation of the PREDICT Prognostication Tool in US Patients With Breast Cancer.
Stabellini N; Cao L; Towe CW; Miller ME; Sousa-Santos AH; Amin AL; Montero AJ
J Natl Compr Canc Netw; 2023 Oct; 21(10):1011-1019.e6. PubMed ID: 37856198
[TBL] [Abstract][Full Text] [Related]
2. Validation of the online prediction tool PREDICT v. 2.0 in the Dutch breast cancer population.
van Maaren MC; van Steenbeek CD; Pharoah PDP; Witteveen A; Sonke GS; Strobbe LJA; Poortmans PMP; Siesling S
Eur J Cancer; 2017 Nov; 86():364-372. PubMed ID: 29100191
[TBL] [Abstract][Full Text] [Related]
3. Validity of the prognostication tool PREDICT version 2.2 in Japanese breast cancer patients.
Zaguirre K; Kai M; Kubo M; Yamada M; Kurata K; Kawaji H; Kaneshiro K; Harada Y; Hayashi S; Shimazaki A; Morisaki T; Mori H; Oda Y; Chen S; Moriyama T; Shimizu S; Nakamura M
Cancer Med; 2021 Mar; 10(5):1605-1613. PubMed ID: 33452761
[TBL] [Abstract][Full Text] [Related]
4. Gene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer: an evidence-based and economic analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2010; 10(23):1-57. PubMed ID: 23074401
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant endocrine therapy in pre- versus postmenopausal patients with steroid hormone receptor-positive breast cancer: results from a large population-based cohort of a cancer registry.
Inwald EC; Koller M; Klinkhammer-Schalke M; Zeman F; Hofstädter F; Lindberg P; Gerstenhauer M; Schüler S; Treeck O; Ortmann O
J Cancer Res Clin Oncol; 2015 Dec; 141(12):2229-40. PubMed ID: 26253629
[TBL] [Abstract][Full Text] [Related]
6. Impact of adjuvant endocrine therapy in older patients with comorbidities and estrogen receptor-positive, node-negative breast cancer-A National Cancer Database analysis.
Tamirisa N; Lin H; Shen Y; Shaitelman SF; Karuturi MS; Giordano SH; Babiera GV; Bedrosian I
Cancer; 2021 Jul; 127(13):2196-2203. PubMed ID: 33735487
[TBL] [Abstract][Full Text] [Related]
7. Real-World Outcomes of Adjuvant Chemotherapy for Node-Negative and Node-Positive HER2-Positive Breast Cancer.
Veitch Z; Khan OF; Tilley D; Ribnikar D; Kostaras X; King K; Tang P; Lupichuk S
J Natl Compr Canc Netw; 2019 Jan; 17(1):47-56. PubMed ID: 30659129
[No Abstract] [Full Text] [Related]
8. Relative effectiveness of adjuvant chemotherapy for invasive lobular compared with invasive ductal carcinoma of the breast.
Marmor S; Hui JYC; Huang JL; Kizy S; Beckwith H; Blaes AH; Rueth NM; Tuttle TM
Cancer; 2017 Aug; 123(16):3015-3021. PubMed ID: 28382636
[TBL] [Abstract][Full Text] [Related]
9. Better predictive value of axillary lymph node (ALN) status after systemic therapy for operable HER2-overexpressing breast cancer: A single-institution retrospective study.
Zhang Y; Mo M; Li JW; Zhou Y; Wu J; Yu KD; Shen ZZ; Shao ZM; Liu GY
Eur J Surg Oncol; 2016 Aug; 42(8):1146-52. PubMed ID: 27365197
[TBL] [Abstract][Full Text] [Related]
10. Ovarian suppression for adjuvant treatment of hormone receptor-positive early breast cancer.
Bui KT; Willson ML; Goel S; Beith J; Goodwin A
Cochrane Database Syst Rev; 2020 Mar; 3(3):CD013538. PubMed ID: 32141074
[TBL] [Abstract][Full Text] [Related]
11. The clinical usefulness of the CTS5 in the prediction of late distant recurrence in postmenopausal women with estrogen receptor-positive early breast cancer.
Tajiri W; Ijichi H; Takizawa K; Koi Y; Masuda T; Ueo H; Koga C; Nakamura Y; Taguchi K; Okamoto M; Tokunaga E
Breast Cancer; 2021 Jan; 28(1):67-74. PubMed ID: 32601800
[TBL] [Abstract][Full Text] [Related]
12. Accuracy of the online prognostication tools PREDICT and Adjuvant! for early-stage breast cancer patients younger than 50 years.
Engelhardt EG; van den Broek AJ; Linn SC; Wishart GC; Rutgers EJT; van de Velde AO; Smit VTHBM; Voogd AC; Siesling S; Brinkhuis M; Seynaeve C; Westenend PJ; Stiggelbout AM; Tollenaar RAEM; van Leeuwen FE; van 't Veer LJ; Ravdin PM; Pharaoh PDP; Schmidt MK
Eur J Cancer; 2017 Jun; 78():37-44. PubMed ID: 28412587
[TBL] [Abstract][Full Text] [Related]
13. A population-based validation of the prognostic model PREDICT for early breast cancer.
Wishart GC; Bajdik CD; Azzato EM; Dicks E; Greenberg DC; Rashbass J; Caldas C; Pharoah PD
Eur J Surg Oncol; 2011 May; 37(5):411-7. PubMed ID: 21371853
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant endocrine therapy alone in patients with node-positive, luminal A type breast cancer.
Park S; Lee SK; Paik HJ; Ryu JM; Kim I; Bae SY; Yu J; Kim SW; Lee JE; Nam SJ
Medicine (Baltimore); 2017 Jun; 96(22):e6777. PubMed ID: 28562530
[TBL] [Abstract][Full Text] [Related]
15. Demographic, tumour, and treatment characteristics of female patients with breast cancer in Sri Lanka; results from a hospital-based cancer registry.
Wijeratne DT; Gunasekera S; Booth CM; Promod H; Jalink M; Jayarajah U; Seneviratne S
BMC Cancer; 2021 Nov; 21(1):1175. PubMed ID: 34732162
[TBL] [Abstract][Full Text] [Related]
16. Impact of Neoadjuvant Versus Adjuvant Chemotherapy on the Extent of Axillary Surgery for Clinically Node-Negative Breast Cancers of Triple-Negative and HER2-Overexpressing Phenotypes.
Thompson JL; Wrubel E; Davis AT; Koehler T; Chung MH; Wright GP
Clin Breast Cancer; 2020 Oct; 20(5):390-394. PubMed ID: 32444317
[TBL] [Abstract][Full Text] [Related]
17. Long term survival of HER2-positive early breast cancer treated with trastuzumab-based adjuvant regimen: a large cohort study from clinical practice.
Bonifazi M; Franchi M; Rossi M; Zambelli A; Moja L; Zambon A; Corrao G; La Vecchia C; Zocchetti C; Negri E
Breast; 2014 Oct; 23(5):573-8. PubMed ID: 24934637
[TBL] [Abstract][Full Text] [Related]
18. Association of Adjuvant Hormone Therapy Timing With Overall Survival Among Patients With Hormone Receptor-Positive Human Epidermal Growth Factor Receptor-2-Negative Early Breast Cancer Without Chemotherapy.
Fu F; Yu L; Zeng B; Chen M; Guo W; Chen L; Lin Y; Hou J; Li J; Li Y; Li S; Chen X; Zhang W; Jin X; Cai W; Zhang K; Chen H; Qiu Y; Nie Q; Wang C; Jacobs L
JAMA Netw Open; 2022 Feb; 5(2):e2145934. PubMed ID: 35166783
[TBL] [Abstract][Full Text] [Related]
19. Locoregional recurrence and survival outcomes by type of local therapy and trastuzumab use among women with node-negative, HER2-positive breast cancer.
Peterson DJ; Truong PT; Sadek BT; Alexander CS; Wiksyk B; Shenouda M; Raad RA; Taghian AG
Ann Surg Oncol; 2014 Oct; 21(11):3490-6. PubMed ID: 24841346
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
